SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Armata Pharmaceuticals, Inc. (ARMP) News

Follow Armata Pharmaceuticals, Inc. (ARMP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ARMP Asset equity Sector Markets 90 days 9 Last 3.01 Updated Nov 12, 2026, 09:05 PM UTC Open live news feed Open ARMP chart & news
M Armata Reports $54.9M Q3 Net Income on $69.6M Loan Fair-Value Gain Armata reported Q3 2026 net income of $54.9 million, compared with a $26.7 million net loss in Q3 2025. The result was primarily driven by a $69.6 million convertible-loan fair-value gain. Its planned AP-SA02 Phase 3 stu EARNINGS | Nov 12, 2026, 09:05 PM UTC L HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target HC Wainwright & Co. reiterated their Buy rating on Armata Pharmaceuticals's stock with a price target of $15.00.The price target implies an upside of 257.1% from the Sep 22 close of $4.20.Key takeaways from the analyst n EQUITY | Sep 23, 2026, 03:04 PM UTC L Armata Gets $3.7M in Additional Funding From Defense Dept. for Bacterial Infection Treatment By Kelly CloonanArmata Pharmaceuticals said it received an additional $3.7 million in non-dilutive funds from the Defense Department to continue developing a treatment for a type of bacterial infection.The biotechnology NEWS | Sep 23, 2026, 11:46 AM UTC H Armata Pharmaceuticals receives $3.7M in DoW funding to support AP-SA02 Phase 3 Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02.Key Highlights:Original SEC Filing: Armata Pharmaceuticals, Inc. [ GEOPOLITICS | Sep 23, 2026, 11:14 AM UTC H Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02 Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC") LIVE | Sep 23, 2026, 11:09 AM UTC H ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development GEOPOLITICS | Sep 23, 2026, 11:00 AM UTC L ARMP - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates ARMP - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates NEWS | Sep 21, 2026, 11:00 AM UTC L ARMP - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference ARMP - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference EQUITY | Sep 10, 2026, 11:00 AM UTC L ARMP - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generati ARMP - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials EQUITY | Sep 03, 2026, 11:01 AM UTC L ARMP Announces Q2 2026 Financial Results ARMP announces financial results for the second quarter 2026 and provides a corporate update EARNINGS | Aug 12, 2026, 08:06 PM UTC L Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02 () -- Armata Pharmaceuticals (ARMP) said Monday it has reached agreement with the US Food and Drug Administration on an agreed initial pediatric study plan for AP-SA02, clearing a regulatory requirement ahead of a potent REGULATION | Jul 13, 2026, 11:47 AM UTC L Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02 Armata Pharmaceuticals... EQUITY | Jul 13, 2026, 11:04 AM UTC M ARMP Receives $2.5M Funding Armata Pharmaceuticals receives $2.5 million in non-dilutive award funding from the U.S. Department of Defense to support AP-SA02 EQUITY | Jun 23, 2026, 11:03 AM UTC